Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma in Sturge-Weber syndrome.

Abstract

AIM:

To evaluate the efficacy of ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma (DCH) in Sturge-Weber syndrome (SWS).

METHODS:

A total of 8 patients with DCH in SWS managed with plaque brachytherapy were retrospectively included. Patients were treated with ruthenium-106 plaque therapy (median apex dose: 83 Gy) at the thickest tumor region. On follow-up, we recorded the tumor thickness, the best-corrected visual acuity (BCVA), subretinal fluid (SRF) status, and complications following treatment.

RESULTS:

At a median follow-up of 43mo, tumor regression was observed in all cases, with a complete resolution of SRF and reduction in tumor-thickness. No radiation complications were recorded during the follow up time.

CONCLUSION:

Ruthenium-106 plaque therapy to the thickest portion of the tumor seems to be a useful treatment in patients with DCH in SWS.

• Authors: Ying-Ying Yu, Xiao-Xin Li, Jian-Hong Liang
• Journal: International journal of ophthalmology (Int J Ophthalmol) Vol. 13 Issue 3 Pg. 513-517 ( 2020) ISSN: 2222-3959 [Print] China
• PMID: 32309192 (Publication Type: Journal Article)
• Copyright: International Journal of Ophthalmology Press.